EMA Begins Review of Rucaparib After Finding of Shorter Survival

Recently published results from the ARIEL4 trial show a significantly longer progression-free survival; but new results show a shorter overall survival.
News Alerts

source https://www.medscape.com/viewarticle/972717?src=rss